ab122 + tas-120 + fluorouracil + cisplatin

**AB122 + TAS-120 + fluorouracil + cisplatin** is a multi-drug investigational combination therapy explored in oncology clinical trials. - **AB122** is a fully human monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), designed to block T-cell suppression by disrupting the PD-1/PD-L1 interaction[1][3][5][7]. - **TAS-120** (also known as futibatinib) is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR1–4), acting as a covalent irreversible FGFR inhibitor[7]. - **Fluorouracil** (5FU) is a pyrimidine analog and antimetabolite that inhibits thymidylate synthase, blocking DNA synthesis in rapidly dividing cells[2][4][6][8]. - **Cisplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking, leading to apoptosis of cancer cells[2][4][6][8]. This combination is being studied in early-phase clinical trials for advanced solid malignancies, including head and neck cancer and biliary tract cancer[7]. The rationale is to combine immune checkpoint inhibition, targeted FGFR blockade, and cytotoxic chemotherapy for synergistic anti-tumor efficacy. The drugs are administered intravenously or orally in cycles according to protocol.

Other names

ab122 + tas-120 + fluorouracil + cisplatin